Sasha Jovanovic
3 min read
Genpact earnings jolt investor focus
Genpact (G) is back in the spotlight after third quarter 2026 earnings, where revenue reached about US$1.39b and net income came in near US$152m, with adjusted earnings topping Wall Street forecasts.
The earnings beat has arrived alongside a sharp 25.6% 1 month share price return and a 23.3% 3 month share price gain. However, Genpact still shows a year to date share price decline of 7.9% and a 1 year total shareholder return slip of 3.1%, suggesting momentum has only recently started to rebuild after a mixed longer term record.
Spot fresh momentum stories like Genpact by scanning our hand picked list of 39 high quality undervalued stocks that are poised for potential rerating.
After a 25.6% one month jump, the question around Genpact now is simple. Has the rerating already played out, or do the current valuation markers still leave meaningful upside on the table?
Most Popular Narrative: 20% Overvalued
Genpact closed at $42.27 against a widely followed fair value estimate of $42.18, so the current price sits almost exactly on that narrative anchor while still reflecting expectations for disciplined contract mix and margin execution.
The rising share of annuitized, non FTE and outcome based contracts, with non FTE revenue surpassing 50% of total revenue in Q2 2026 and more than 70% of ATS revenue both annuitized and non FTE, increases the potential for more recurring revenue and steadier earnings over time.
See why 19 investors see Genpact as 0% overvalued.
Result: Fair Value of $42.18 (ABOUT RIGHT)
Still, Genpact’s effort to exit lower value contracts could drag reported growth if Advanced Technology Solutions and agentic deals do not fill the gap quickly enough.
Find out about the key risks to this Genpact narrative.
Another View: Genpact’s earnings multiple sends a different message
While the fair value narrative pegs Genpact close to $42.18, the market’s simple P/E math points in another direction. The stock trades on roughly 12x earnings, compared with about 19x for peers and a fair ratio of 20.2x that our model suggests the market could move toward. That gap frames either a valuation cushion or a sign investors still want a bigger safety margin before paying up.
To see what the numbers say about this price, look at the full valuation breakdown in See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals on Genpact’s value story so far. Consider the situation while sentiment is still forming and weigh both sides through the 5 key rewards and 1 important warning sign.
